Emerald Advisers LLC Purchases 14,302 Shares of LivaNova PLC (NASDAQ:LIVN)

Emerald Advisers LLC boosted its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 2.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 695,505 shares of the company's stock after purchasing an additional 14,302 shares during the period. LivaNova makes up approximately 1.4% of Emerald Advisers LLC's holdings, making the stock its 14th biggest position. Emerald Advisers LLC owned about 1.28% of LivaNova worth $36,542,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LIVN. Primecap Management Co. CA raised its holdings in shares of LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company's stock valued at $327,889,000 after acquiring an additional 44,049 shares during the period. Vanguard Group Inc. raised its holdings in shares of LivaNova by 3.5% during the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company's stock valued at $102,537,000 after acquiring an additional 62,480 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of LivaNova by 204.3% during the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock valued at $70,479,000 after acquiring an additional 863,157 shares during the period. Magnetar Financial LLC raised its holdings in shares of LivaNova by 8.1% during the second quarter. Magnetar Financial LLC now owns 814,452 shares of the company's stock valued at $44,648,000 after acquiring an additional 61,114 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock valued at $41,889,000 after acquiring an additional 25,277 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LIVN. Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday. Needham & Company LLC restated a "buy" rating and set a $75.00 price target on shares of LivaNova in a report on Thursday. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research note on Thursday. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective on the stock. Finally, Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $69.17.

LivaNova Stock Down 0.9 %

Shares of LIVN traded down $0.49 during mid-day trading on Friday, hitting $51.13. 441,992 shares of the company's stock were exchanged, compared to its average volume of 424,872. The firm has a fifty day moving average of $51.13 and a two-hundred day moving average of $53.13. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.47. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 121.74 and a beta of 1.01. The company has a quick ratio of 2.94, a current ratio of 3.37 and a debt-to-equity ratio of 0.49.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.66 by $0.15. LivaNova had a net margin of 1.91% and a return on equity of 13.81%. The company had revenue of $318.60 million for the quarter, compared to analyst estimates of $305.05 million. On average, sell-side analysts forecast that LivaNova PLC will post 2.58 earnings per share for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.